Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. We pooled two cohorts of newly diagnosed ...

Studies demonstrating high response rates and manageable safety profiles, along with FDA approvals, have supported bispecific antibodies as promising treatment options for follicular lymphoma. At the ...

Chronic incurability and variable remission durability drive anticipatory anxiety, even years after treatment, because relapse timing is inherently unpredictable. Benign symptoms such as sweats, ...

There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma that affects white blood cells called ...

Follicular lymphoma is graded 1 to 3 based on how many large B cells (centroblasts) appear under a microscope, which signals how fast it may grow. Grade 1 and 2 follicular lymphoma are usually slow ...

Real-world treatment patterns and outcomes among older patients with follicular lymphoma show significant heterogeneity, with 13,423 Medicare beneficiaries aged ≥ 65 years followed through 2019. Over ...

Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the ...

The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space. The future treatment landscape for ...

The National Institute for Health and Care Excellence (NICE) has recommended epcoritamab (Tepkinly, AbbVie) as a treatment option for adults with relapsed or refractory follicular lymphoma after two ...

We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 ...